

Cancer Control Program Community Oncology Committee

200 First Street, SW
Rochester, MN 55905
P: 507-266-9202
F: 507-284-1803

www.allianceforclinicaltrialsinoncology.org



Robert J. Behrens, M.D.
Peggy Kemeny, M.D.
Jon Strasser, M.D.
Co-Chairs

Agenda Community Oncology Committee Leadership Meeting May 13, 2016 4:30 – 7:30 PM CT

Meeting available by teleconference: Dial 800-501-8979 Access Code: 2107872

Present	Committee Leadership Members:		
	Robert J. Behrens, MD	Co-chair	rbehrens@cancercenterofiowa.com
	Peggy Kemeny, MD	Co-chair	kemenym@nychhc.org
	Jon Strasser, MD	Co-chair	jstrasser@christianacare.org
	Jan C. Buckner, MD	CCP Program Director	buckner.jan@mayo.edu
	Jacqueline M. Lafky, MS	CCP Program Manager	lafky.jacqueline@mayo.edu
	Deb Dickman	CCP Administrative Assistant	dickman.deborah@mayo.edu
	Neil Abrahams, MD	Pathology Representative	NAbrahams@mhs.net
	James N. Atkins, MD	Community BoD Representative	jnatkins@juno.com
	Bryan A. Faller, MD	CCDR Representative	baf3600@bjc.org
	Patrick Gavin, RPh	Patient Advocate Representative	pat@gavin-consulting.com
	Linda M. Gordon, MD	Imaging Representative	lindamgordon@gmail.com
	David Grisell, DO	Community BoD Representative	dgrisell@ghs.org
	Philip J. Stella, MD	Community BoD Representative	Philip.Stella@stjoeshealth.org
	Elizabeth White	CRP Representative	ecwhite@novanthealth.org
	Mary Beth Wilwerding, RN	Oncology Nursing Representative	mwilwerding@mvcc.cc

I. Welcome and Announcements (5 minutes)

- CCP Executive Officer, Paul Reiter, PhD

II. Mentoring and Development of Young Community Investigators and Research Leaders for the Future (25 minutes)

James Bearden, MD and Amy Curtis, MD

III. Strategies to Facilitate Research Billing Compliance: Update on an ASCO/NCI Initiative (25 minutes)

Connie M. Szczepanek, BSN; Michael Kelly, MA; Andrea M. Denicoff, RN, MS, ANP

IV. Protocol Presentations: Recent or Soon to Open Studies (10-15 minutes each)

- Molecular Analysis for Therapy Choice (NCI-MATCH)
Barbara A. Conley, MD
- A191402: Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men
Jon Tilburt, MD
- A211401: Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Ivana Croghan, PhD
- A221208: Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases
Paul Brown, MD presenting on behalf of Caroline Chung, MD

V. Protocol Presentations: Studies Struggling with Accrual (10 minutes each)

- A. A221101: A Phase III Randomized, Double-blind Placebo Controlled Study of Armodafinil (Nuvigil) to Reduce Cancer-related Fatigue in Patients with Glioblastoma Multiforme
Paul Brown, MD presenting on behalf of Alyx Porter, MD
- B. A221102: Randomized Double-blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias
Charles Loprinzi, MD
- C. 30901: Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients with Malignant Pleural Mesothelioma Without Progression after First-line Chemotherapy
Arek Dudek, MD, PhD
- D. A011203: A Randomized Phase II Trial of Tamoxifen versus Z-endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Matthew Goetz, MD

VI. CCDR Activities (10 minutes each)

- A. NCI CCDR Updates
Kathleen Castro, RN, MS, AOCN
- B. Alliance CCDR Committee Updates
George Chang, MD
 - New Concept: Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (**OPTI-Surg**)
Emily Finlayson, MD
- C. Q&A Session
Kathleen Castro, RN, MS, AOCN & George Chang, MD

VII. Other Business